Long-Term Sequential Dual Antiplatelet Therapy Based on Cilostazol in Symptomatic Intracranial Arterial Stenosis: A Real-World Cohort Study
Key facts
- Who runs it
- Second Affiliated Hospital of Soochow University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 990 people, planned
- Started
- 1 Mar 2026
- Expected to end
- 30 Jun 2029
- Type of study
- Observational, 2 groups
- Treatments tested
- Cilostazol-Based Dual Antiplatelet Therapy
- Single Antiplatelet Therapy
- Record updated
- 13 November 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Age: 18-80 years old
- Acute mild non-cardioembolic stroke
- Ischemic stroke or transient ischemic attack (TIA) occurring 2 to 4 weeks prior to enrollment
- NIHSS score ≤15 at enrollment and pre-stroke mRS score ≤2
- Ischemic stroke or TIA attributable to the territory of the qualifying intracranial artery
- Symptomatic 70%-99% intracranial atherosclerotic stenosis confirmed by DSA, CTA, or MRA
Who cannot take part
- Current or previous severe heart failure
- Severe bleeding event within the previous 6 months, including spontaneous intracranial hemorrhage, major gastrointestinal bleeding, or other bleeding requiring blood transfusion
- High-risk cardioembolic source requiring or potentially requiring long-term anticoagulation, including persistent or paroxysmal atrial fibrillation, mechanical heart valve or severe valvular disease, intracardiac thrombus, recent myocardial infarction with significant wall-motion abnormality, or severe cardiomyopathy
- Stroke or TIA caused by nonatherosclerotic disease, including moyamoya disease, vasculitis, arterial dissection, or other definite nonatherosclerotic causes
- Known allergy or serious adverse reaction to cilostazol, aspirin, clopidogrel, ticagrelor, or other antiplatelet agents
- Significant bleeding tendency or coagulation abnormality
- Medical condition requiring long-term oral anticoagulation
- Active malignancy or other serious illness with a life expectancy of less than 1 year
- Severe cognitive impairment or psychiatric illness that would prevent adherence to study treatment or long-term follow-up
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to evaluate whether long-term dual antiplatelet therapy (DAPT) with cilostazol is associated with a lower risk of recurrent symptomatic ischemic stroke or all-cause mortality compared with single antiplatelet therapy (SAPT) in patients with symptomatic moderate-to-severe intracranial arterial stenosis following the completion of standard DAPT.
The 2 groups in the trial
- Cilostazol-Based Dual Antiplatelet Therapy
Participants who receive cilostazol 50 mg twice daily in combination with aspirin 100 mg once daily, clopidogrel 75 mg once daily, or ticagrelor 90 mg twice daily for 12 months according to routine clinical practice.
- Single Antiplatelet Therapy
Participants who receive single antiplatelet therapy with aspirin 100 mg once daily, clopidogrel 75 mg once daily, or ticagrelor 90 mg twice daily for 12 months according to routine clinical practice.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Secondary Preventive Effect of Long-term Sequential Dual Antiplatelet Therapy Based on Cilostazol in Cerebral Infarction Patients With Symptomatic Moderate to Severe Intracranial Arterial Stenosis: A Real-World Cohort Study (SPDACSIS-COH)
- Fit questions
- Built from NCT07935408, who can take part
- Record updated
- 13 November 2026